Eton Pharmaceuticals, Inc. (ETON)
| Market Cap | 1.79B +294.4% |
| Revenue (ttm) | 141.06M +100.6% |
| Net Income | 49.86M |
| EPS | 1.60 |
| Shares Out | 28.84M |
| PE Ratio | 38.86 |
| Forward PE | 24.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 172,439 |
| Open | 63.75 |
| Previous Close | 63.65 |
| Day's Range | 61.71 - 64.63 |
| 52-Week Range | 14.27 - 70.64 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 80.75 (+29.97%) |
| Earnings Date | Nov 5, 2026 |
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing vari... [Read more]
Financial Performance
In 2025, Eton Pharmaceuticals's revenue was $79.95 million, an increase of 104.94% compared to the previous year's $39.01 million. Losses were -$4.60 million, 20.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price target is $80.75, which is an increase of 29.97% from the latest price.
News
Eton Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
The strategy pairs a diversified ultra-rare disease portfolio and patient-access focus with lean operations and recurring launches. Q3 2026 revenue of $58 million reached the $200 million goal five quarters early; multiple pipeline launches and readouts are planned for 2027–2028.
Eton Pharmaceuticals price target raised to $81 from $70 at B. Riley
B. Riley raised the firm’s price target on Eton Pharmaceuticals (ETON) to $81 from $70 and keeps a Buy rating on the shares post the Q3 report. The company reported…
Eton Pharmaceuticals price target raised to $82 from $78 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $82 from $78 and keeps a Buy rating on the shares. The firm notes Eton delivered a substantial beat…
Eton Pharmaceuticals price target raised to $80 from $70 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Eton Pharmaceuticals (ETON) to $80 from $70 and keeps a Buy rating on the shares. The firm views the company’s Q3 report…
Eton Pharmaceuticals price target raised to $80 from $68 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on Eton Pharmaceuticals (ETON) to $80 from $68 and keeps a Buy rating on the shares. The firm said 3Q delivered…
Eton Pharmaceuticals reports Q3 EPS 50c, two estimates 37c
Reports Q3 revenue $57.9M, consensus $42.21M. Top-line growth was driven by the addition of revenue from Hemangeol and higher product sales across key products including Increlex, Alkindi Sprinkle, Ga...
Eton Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 158% YoY to $57.9M, with 49% adjusted EBITDA margin and FY2026 revenue guidance raised to more than $175M. Pipeline expansion and potential 2027 launches strengthen the growth outlook.
Eton Pharmaceuticals Earnings release: Q3 2026
Eton Pharmaceuticals released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Eton Pharmaceuticals Quarterly report: Q3 2026
Eton Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 5, 2026.
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1....
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability
Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN ® participants Hepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with ...
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis,...
Eton Pharmaceuticals initiates program for infantile and epileptic spasms
Eton Pharmaceuticals (ETON) announced ET-900, a new development program evaluating mecasermin injection for the treatment of infantile and epileptic spasms. Mecasermin is a recombinant form of IGF-1 a...
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
DEER PARK, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
DEER PARK, Ill., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals price target raised to $78 from $76 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $78 from $76 and keeps a Buy rating on the shares following the company’s exclusive licensing agreement of Libervant…
Eton and Aquestive announce license and supply agreement for Libervant
Eton Pharmaceuticals (ETON) and Aquestive Therapeutics (AQST) announced that they have entered into an exclusive license agreement and a supply agreement covering the U.S. and its territories for LIBE...
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
DEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
Eton Pharmaceuticals announces U.S. availability of Impavido
Eton Pharmaceuticals (ETON) announced that the company has launched Impavido capsules. Eton Pharmaceuticals now holds exclusive commercialization rights for Impavido in the United States.
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
DEER PARK, Ill., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
Eton Pharmaceuticals participates in a conference call with Craig-Hallum
Healthcare Analyst Hewitt holds a conference call with President & CEO Stephen Gunstream on September 16 at 2 pm hosted by Craig-Hallum. Webcast Link
Eton Pharmaceuticals management to meet with Craig-Hallum
Meeting to be held in Denver on September 22 and in Salt Lake City on September 23 hosted by Craig-Hallum.
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
Eton Pharmaceuticals participates in a conference call with Craig-Hallum
Conference call with management to be held on August 18 at 1 pm hosted by Craig-Hallum.